Is Saroja Pharma In overvalued or undervalued?
As of September 5, 2025, Saroja Pharma is fairly valued with a PE ratio of 20.20, outperforming the Sensex and positioned competitively against peers like Dr. Reddy's Labs, while significantly lower than Sun Pharma and Divi's Lab.
As of 5 September 2025, Saroja Pharma's valuation grade has moved from expensive to fair, indicating a shift in its market perception. The company is currently fairly valued. Key ratios include a PE ratio of 20.20, an EV to EBIT of 9.14, and a ROCE of 14.31%. When compared to peers, Saroja Pharma's PE ratio is significantly lower than Sun Pharma's 33.33 and Divi's Lab's 69.2, both of which are classified as expensive. In contrast, Dr. Reddy's Labs, which is attractive, has a PE ratio of 18.65, suggesting that Saroja Pharma is competitively positioned within its peer group. Notably, Saroja Pharma has outperformed the Sensex in the past week and month, with returns of 8.15% and 43.75%, respectively, reinforcing its valuation narrative.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
